...ly invasive surgery is founded on superior medical...-Chip cameras, 1-Chip cameras, Light sources, Coup...nding needs., ,Superior resolution and color repr...meras, and are the benchmark by which all other me...
...ra System provides easy-to-use features, auto iris...amera head construction is based on Solos durable ...era System, International (GS9900-PAL) includes: ,...rd and video cables , (GS 9905) Camera head with 3...
Provides a combination of concentrated cold / hot and compression for the elbow
Provides extended cold therapy for acute, chronic, or post-surgical applications. Cryotherapy can reduce pain, swelling and speed recovery.
Medicine Products:(Date:10/13/2008)...eading Content Rights Management System, Supports... Content Spend, WEST CHESTER, Pa., Oct. 13 /PRNew...ding global pharmaceutical manufacturer has integr...primary platform for the,secure distribution, data...cs for their new product video content. Imperium i...
(Date:10/13/2008)...swire/ -- The National Coalition for,Quality Color...ncerns over,the National CT Colonography Study pub...Medicine. The evidence must be closely evaluated, ...y is not without significant,potential risks. The ...py,remains the "Gold Standard" for colorectal canc...
(Date:10/13/2008)...blem in daily life, survey shows, PORTLAND, Ore.,...three-quarters of people living with psoriasis say...e, according to a National Psoriasis,Foundation 20...viduals with psoriasis and psoriatic arthritis,als...ly lives, shapes their,feelings about themselves a...
(Date:10/13/2008)...swire/ -- During the Pri-Med New York,conference a...are providers,took a 20-question quiz prepared by ...n Somerset, NJ. The quiz tested basic knowledge of..., EMR software, and healthcare,administration., T... The average number,of correct answers was only 7....
Breaking Medicine News(10 mins):Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3Health News:National Psoriasis Foundation Releases 2008 Study Results 2Health News:MTBC Practice Management Quiz Sends Message to Doctors: There is Real Room for Improvement or a Need to Outsource 2(Date:10/8/2008)...s Research That May Offer New Hope to,Heart Failur...nally, over 3,000 people are,waiting for a heart t...alf,of those will receive a transplant. Now, pione... paving the way for how to treat congestive heart,...ews Release, go to:, http://www.prnewswire.com/mnr...
(Date:10/8/2008)...tists Expand Testing Using Cellular ...ne, Oct. 8 /- Wild Blueberry antioxid...sults from a new study,showing Wild Blueberries ou...like apples, bananas, red grapes and strawberries ... Activity (CAA) assay. New research,published in t...
(Date:10/8/2008)...of Poly-ICR as Vaccine Adjuvant, SAN DIEGO, Oct. ...als,Corporation (TSX: NVN) today presented positiv...ary Toll-like Receptor 3 agonist, Poly IC-Poly,Arg...08 in Lyon, France.,Study results demonstrated Pol...e Toll-like Receptor 3 (TLR3) pathway. Data showed...
(Date:10/8/2008)...ical improvement in patients with pulmonary a...t options have limited benefit for this debilitati...essel disease, -- Imatinib mesylate, available ...s, known to inhibit protein associated with PAH, ...inib mesylate in PAH in 2009 EAST HANOVER, N...
Breaking Medicine Technology:Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 2Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 3Wild Blueberries Take Top Spot in New Antioxidant Research Study 2Wild Blueberries Take Top Spot in New Antioxidant Research Study 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 2Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 4Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 5Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 2Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 3Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 4Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 5Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 6Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 7Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 8Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 9Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 10Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 11Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 12ATS Medical to Present at the 19th Annual Piper Jaffray Health Care Conference 6688 1ATS Medical to Present at the 19th Annual Piper Jaffray Health Care Conference 6688 2Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation 1867 1Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation 1867 2ARIUS to present at BioNorth Biotechnology and Life Sciences Conference 1863 1ARIUS to present at BioNorth Biotechnology and Life Sciences Conference 1863 2Pharsight Uses FDA Disease Model to Support Oncology Drug Development 882 1Pharsight Uses FDA Disease Model to Support Oncology Drug Development 882 2Pharsight Uses FDA Disease Model to Support Oncology Drug Development 882 3... 2007 /PRNewswire/ --,Pieris AG, a bio-pharmaceuti...s of targeted human protein therapeutics, today an...effective products for,the potential treatment of ...calin(R) candidate, the Company reports that the,p...of action via,the lungs. , PRS-060 has been select...
... -- Portola,Pharmaceuticals, Inc. announced positi...an oral Factor Xa inhibitor, today at the XXI,Cong...d Haemostasis,(ISTH) in Geneva, Switzerland. The E...ive, and well tolerated for the,prevention of veno...ing total knee replacement (TKR) surgery. Portola ...
Other Medicine Technology:Pieris Progresses Proprietary Asthma Program: Validation of,Pulmonary Delivery of Anticalin-Based Protein Product Candidate 2Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis 2Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis 3Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis 4